PP65 Antibody [CMV101] | 33-243

PP65 Antibody [CMV101] | 33-243 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Cytomegalovirus

Homology: N/A

Immunogen: Recombinant Cytomegalovirus p65 protein was used as the immunogen for this PP65 antibody.

Research Area: Other

Tested Application: ICC, IF, E

Application: ELISA: order BSA-free format for coating
Immunocytochemistry (Acetone or paraformaldehyde fixed) : 0.5-1 ug/ml for 30 min
IF: 0.5-1 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the PP65 antibody to be titered up or down for optimal performance.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: CMV101

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: N/A

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF) , urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.